ARC-T cells

ARC-T cells (Antigen Receptor Complex T cells) are a novel, genetically modified autologous T cell therapy platform developed by Arcellx. These engineered T cells are designed to be controlled by the administration of soluble protein antigen-receptor X-linkers (SparX proteins), which target specific antigens on cancer or diseased cells. The ARC-T system enables precise control over the activation, silencing, and reprogramming of the therapeutic T cells through dose modulation and selection of SparX proteins. This approach allows for targeting multiple antigens to address tumor heterogeneity and minimize toxicities. The primary mechanism involves redirecting patient-derived T-cells to recognize and kill cancer or diseased cells only in the presence of a matching SparX protein bound to a disease-specific antigen, such as B-cell maturation antigen in multiple myeloma or CD123 in acute myeloid leukemia[1][3][4][5].

Other names

Antigen Receptor Complex T cells